Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng/ml

• Published in: Future oncology (London, England) Vol. 13; no. 20; pp. 1793 - 1800
• Main Authors: Andras, Iulia, Crisan, Nicolae, Vesa, Stefan, Rahota, Razvan, Romanciuc, Florina, Lazar, Andrei, Socaciu, Carmen, Matei, Deliu-Victor, de Cobelli, Ottavio, Bocsan, Ioan-Stelian, Coman, Radu-Tudor
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.08.2017
• Subjects: Accuracy; Aged; Amino acids; Antigens; Biomarkers; Biopsy; Diagnosis, Differential; Discriminant analysis; Humans; Male; Medical screening; Metabolites; Metabolome; metabolomics; Metabolomics - methods; Middle Aged; Mortality; NMR; Nuclear magnetic resonance; Patients; prediction score; Prognosis; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; ROC Curve; Software; Systematic review; Ultrasonic imaging; Variables; biopsy; prostate cancer; prediction score; metabolomics
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2017-0078

To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy. Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed. Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0.779; p < 0.001). These results were validated in a subgroup of patients, showing similar accuracy (p = 0.1). For patients with prostate specific antigen (PSA) less than 10 ng/ml, the score showed a Se 80.95%, Sp 64.52% for the detection of PCa at biopsy. Metabolomic analysis can predict the outcome of the first systematic biopsy.